



# DEA TOX

DRUG ENFORCEMENT ADMINISTRATION  
TOXICOLOGY TESTING PROGRAM

# QUARTERLY REPORT

**Fourth Quarter – 2023**



**U.S. Department of Justice  
Drug Enforcement Administration  
Diversion Control Division  
Drug and Chemical Evaluation Section**

# Contents

<b>Introduction .....</b>	<b>3</b>
<b>Summary.....</b>	<b>4</b>
<b>Traditional Illicit Drugs .....</b>	<b>7</b>
<b>Prescription and Over the Counter Drugs .....</b>	<b>9</b>
<b>Dietary Supplement Stimulants .....</b>	<b>12</b>
<b>Precursors/Additives/Impurities .....</b>	<b>13</b>
<b>Drug Products .....</b>	<b>14</b>
<b>Public Domain Notice .....</b>	<b>15</b>

## Introduction

The Drug Enforcement Administration's Toxicology Testing Program (DEA TOX) began in May 2019 as a surveillance program aimed at detecting new psychoactive substances within the United States. In response to the ongoing synthetic drug epidemic, the Drug Enforcement Administration (DEA) awarded a contract with the University of California at San Francisco (UCSF) to analyze biological samples generated from overdose victims of synthetic drugs.

In many cases, it can be difficult to ascertain the specific substance responsible for the overdose. The goal of DEA TOX is to connect symptom causation to the abuse of newly emerging synthetic drugs (e.g. synthetic cannabinoids, synthetic cathinones, synthetic opioids, other hallucinogens, etc.).

DEA has reached out to local health departments, law enforcement partners, poison centers, drug court laboratories, hospitals, and other medical facilities to offer testing of leftover or previously collected samples for analysis of synthetic drugs. DEA TOX is interested in patients thought to have ingested a synthetic drug, where the traditional drug screen has produced little or no viable options to explain the symptoms exhibited by the patient (alcohol and THC are exempted). DEA TOX may approve testing of unused biological samples or on occasion non-biological samples from a medical facility or law enforcement partner only.

Requests for testing may be submitted directly to DEA TOX ([DEATOX@DEA.GOV](mailto:DEATOX@DEA.GOV)). Upon explicit approval of the request for testing of specific samples, the originating laboratory is invited to send their samples to the Clinical Toxicology and Environmental Biomonitoring (CTEB) Laboratory at UCSF. DEA covers the full cost of analysis for each sample approved for testing. Using liquid chromatography quadrupole time-of-flight mass spectrometry, synthetic drugs identified within the samples are confirmed and quantified.

The CTEB laboratory currently maintains a comprehensive drug library consisting of 1236 drugs, of which 966 are new psychoactive substances.

This publication presents the results of cases analyzed and completed by the CTEB laboratory from October 1, 2023, through December 31, 2023. Confirmed levels denoted in the tables below with a defined range represent the low and high concentrations reported when the frequency of detection is greater than one.

## Summary



Between October 1, 2023 and December 31, 2023, 136 biological samples from 119 cases originating from 15 states namely, California (8), Florida (2), Illinois (14), Indiana (1), Kentucky (13), Louisiana (5), Massachusetts (2), Maryland (8), Nebraska (9), New Mexico (3), Oregon (2), Tennessee (36), Texas (1), Utah (1), and Washington (14) were analyzed by DEA TOX. These samples were analyzed for NPS, TID, prescription or OTC drugs, DSS, and P/A/I. The biological samples submitted consisted of 31 serum, 5 plasma, 83 whole blood, and 17 urine samples. Twenty drug product samples were also analyzed originating from California (2), Illinois (1), Kentucky (2), Massachusetts (1), and Washington (14).

DEA TOX identified and confirmed a total of 838 drugs and metabolites that consisted of 79 NPS detections, 325 TID detections<sup>1</sup>, 338 prescription or OTC drug detections, 11 DSS, and 85 P/A/I detections during this reporting period (Fig. 1A). While some drugs identified could be placed in more than one category, for purposes of this report and for consistency, DEA TOX placed such substances in a single category only. Many prescription drugs that are commonly abused and encountered are listed as TID. Substances that are not approved by the Food and Drug Administration for medical use within the U.S. are considered NPS.

A breakdown of the 838 total drug and metabolite confirmations demonstrated 105 different drugs, which consisted of 12 NPS, 16 TID, 68 prescription or OTC drugs, 3 DSS, and 6 P/A/I (Fig. 1B).

**Of the cases submitted this quarter, 53 out of the 119 cases (44.5%) detected at least one NPS. In addition, 61 out of the 119 cases (51.3%) contained fentanyl.**

**For the fourth quarter 2023, the frequency in which an NPS was identified will also note the number of fatal cases. For example, a frequency denoted as 12[5] would refer to 12 total cases, of which 5 were fatal.**



<sup>1</sup> Out of the 325 TID detections, fentanyl accounted for 56 (17%) of these detections.

# New Psychoactive Substances

DEA TOX confirmed 55 detections comprising of 12 NPS<sup>s</sup> (Table 1) from three different classes of drugs (Figure 2A) in biological samples in the fourth quarter of 2023. The total encounters for each NPS class are summarized in Figure 2B. An additional 24 NPS detections from drug products are described in Table 6.

Figure 2A. Number of Substances Identified for Each NPS Class





Figure 2B. Total Encounters for Each NPS Class



**Drug Enforcement Administration – Toxicology Testing Program**

**Table 1. NPS detected in Biological Samples – Fourth Quarter 2023**

Drug Class	Drug	Freq. [Fatal]	States Found*	Confirmed Levels (ng/mL)**			
				S	P	WB	U
Benzo-diazepine (4)	8-Amino Clonazolam	5 [4]	IL, TN(4)			0.7-3.8	36.7
	Bromazolam	31 [28]	CA(3), IL(2), NE(2), NM, TN(21), TX, WA	0.5-151		0.3-233	1.2
	Flualprazolam	1 [1]	TN			27.0	
	Flubromazepam	1 [1]	WA	48.5			
Cannabinoid (2)	11-nor-9-carboxy-delta-8-THC	1 [0]	KY	61.7			
	MDMB-4en-PINACA	1 [0]	KY			1.1	
	MDMB-4en-PINACA acid metabolite	1 [0]	KY			72.4	
Opioid (6)	7-OH Mitragynine	1 [0]	KY				24.8
	Brorphine	1 [0]	IL			0.6	
	Despropionyl <i>para</i> -fluorofentanyl	1 [1]	WA	1.3			
	Metonitazene	3 [3]	TN(3)			1.1-14.8	
	Mitragynine	3 [3]	NE, TN(2)	117		1.1-103	
	<i>N</i> -Methyl Norfentanyl	1 [1]	WA	0.5			
	<i>para</i> -Fluorofentanyl	3 [3]	TN, WA(2)	0.2-4.7		0.1	
	Tianeptine	1 [1]	NE			4570	

\* CA – California; IL – Illinois; KY – Kentucky; NE – Nebraska; NM – New Mexico; TN – Tennessee; TX – Texas, WA – Washington.

\*\*S – Serum; P – Plasma; WB – Whole Blood; U – Urine

§ - Parent drugs or metabolites are only counted once for the number of drugs detected in Tables 1-5. If only a metabolite is encountered in the absence of a parent drug, it will still be counted as a unique drug. Both parent drugs and metabolites are counted as detections.

## Traditional Illicit Drugs

DEA TOX confirmed 291 detections of 16 TIDs<sup>s</sup> (Table 2) in biological samples in the fourth quarter of 2023. Thirty-four additional TID detections from drug products are described in Table 6.

**Table 2. TID Detected in Biological Samples – Fourth Quarter 2023**

Drug Class	Drug	Freq.	States Found*	Confirmed Levels (ng/mL)**			
				S	P	WB	U
Amphetamine (3)	4-OH Methamphetamine	2	NE, TN	2.2		30	
	Amphetamine	10	CA, NE(2), OR, TN(6)	911		2.6-436	
	Methamphetamine	27	CA(2), KY(2), NE(3), NM, OR, TN(13), WA(5)	13.8-14100		13.7-1580	18.7
	MDMA	1	IL	289			
	HMMA	1	IL				20.3
Arylcyclohexylamine (1)	Ketamine	4	IN, KY, TN (2)	63.5		53.6-124	61.8
Cannabinoid (1)	11-nor-9-carboxy-delta-9-THC	7	CA, KY, NE, TN(3), UT		86.8	33.5-976	69.2
	11-hydroxy-delta-9-THC	1	TN			113	
	Delta-9-THC	1	TN			45.7	
Cocaine (1)	Benzoylcegonine	37	IL(8), IN, KY(3), MA(2), NE(4), TN(11), WA(8)	7.2-4100	32.4	3.8-2530	24.8-1600
	Cocaethylene	7	IL, KY, NE(2), TN(2), WA	NQ		NQ	
	Cocaine	22	IL(4), KY, NE(4), TN(9), WA(4)	2.7-94.7		0.3-144	
	Ecgonine Methyl Ester	28	IL(8), KY, NE(2), TN(10), WA(7)	NQ		21.4-32	NQ

**Drug Enforcement Administration – Toxicology Testing Program**

**Table 2 (Continued). TID in Biological Samples – Fourth Quarter 2023**

Drug Class	Drug	Freq.	States Found*	Confirmed Levels (ng/mL)**			
				S	P	WB	U
Opioids (8)	Beta-hydroxy Fentanyl	10	IL(2), KY, TN(5), WA(2)	1.8-4.3		0.3-5.2	12.3-410
	Codeine	4	IL, TN(3)			2.2-4.9	11.7
	Desmethyl-cis-Tramadol	2	NM, TN	436		1.7	
	Fentanyl	56	CA, IL(8), KY(5), MA, NE(5), NM(2), TN(22), TX, WA(11)	4.9-122	3.4	1.1-100	2.9-5730
	Norfentanyl	41	IL(5), KY(6), NE(2), NM, TN(18), TX, WA(8)	0.5-235		0.2-30.9	8.5-25600
	Hydrocodone	5	CA, TN(3), WA	2.1-3.0		0.4-27.4	
	Hydromorphone	3	CA, IL, TN			8.8-32.7	4940
	Morphine	9	IL(2), NE, TN(5), WA	1.8		1.9-33.9	508
	Oxycodone	5	TN(5)			16.6-111	
	Tramadol	3	IL, NM, TN	7790		1.6-13.3	298
Stimulant Alkaloids (1)	Nicotine	4	CA, IL(2), NE			33.5-94.4	
Tryptamines (1)	Psilocin	1	KY				2320

\* CA – California; IL – Illinois; IN – Indiana; KY – Kentucky; MA – Massachusetts; NE – Nebraska; NM – New Mexico; OR – Oregon; TN – Tennessee; UT – Utah; WA - Washington

\*\*S – Serum; P – Plasma; WB – Whole Blood; U – Urine; NQ – not quantified

§ - Parent drugs or metabolites are only counted once for the number of drugs detected in Tables 1-5. If only a metabolite is encountered in the absence of a parent drug, it will still be counted as a unique drug. Both parent drugs and metabolites are counted as detections.



## Prescription and Over the Counter Drugs

DEA TOX confirmed 330 detections of 68 prescription or OTC drugs<sup>§</sup> (Table 3) in the fourth quarter of 2023. Eight additional PD/OTC drugs detections are described in Table 6. Drugs for the prescription/OTC drugs panel are not typically quantitated unless specifically requested thus “Confirmed Levels” are not provided.

**Table 3. Prescription or OTC drugs detected in Biological Samples – Fourth Quarter 2023**

Drug Class	Drug	Freq.	States Found*
Amphetamine (1)	Pseudoephedrine	1	TN
Anesthetic (1)	Lidocaine	18	CA (2), FL, IL, KY, NE, NM, TN (8), WA (3)
Antacid (1)	Cimetidine	1	NE
Antibiotic (1)	Levofloxacin	1	NE
Anticoagulant (1)	Warfarin	1	TN
Anticonvulsant (5)	Carbamazepine	1	TN
	Gabapentin	17	CA, KY (3), NE (3), TN (8), WA (2)
	Lamotrigine	2	TN, WA
	Levetiracetam	6	CA, IL (2), MA (2), TN
	Topiramate	1	IL
Antidepressant (10)	Amitriptyline	2	NE, TN
	Citalopram	3	IL, NE, TN
	Duloxetine	1	MD
	Fluoxetine	1	OR
	mCPP**	1	WA
	Mirtazapine	5	IL, LA, NE, TN, WA
	Norfluoxetine**	1	OR
	Nortriptyline**	2	MD, NE
	Paroxetine	1	TN
	Protriptyline	1	TN
	Sertraline	7	IL, KY (2), LA, NE (2), TN
	Trazodone	4	FL, TN, WA (2)
	Venlafaxine	1	TN
Antidiabetic (1)	Metformin	1	TN

\*\*Compounds are expected metabolites of parent drugs, as follow:

Expected Metabolite	Parent Drug
mCPP	Trazodone
Norfluoxetine	Fluoxetine
Nortriptyline	Amitriptyline

**Drug Enforcement Administration – Toxicology Testing Program**

**Table 3 (Continued). Prescription or OTC drugs in Biological Samples – Third Quarter 2023**

<b>Drug Class</b>	<b>Drug</b>	<b>Freq.</b>	<b>States Found*</b>
Antihistamine (7)	Chlorpheniramine	2	FL, NE
	Diphenhydramine	27	CA, FL, IL (7), KY (3), LA, MD, NE, TN (11), WA
	Doxylamine	3	IL, MD, TN
	Hydroxyzine	6	IL, KY, TN (4)
	Loratadine	1	OR
	Norpseudoephedrine	1	KY
	Promethazine	4	KY, OR, TN, WA
Antipsychotic (5)	Aripiprazole	8	IL (2), MD (2), TN (3), WA
	Haloperidol	2	NE, UT
	Olanzapine	8	IL, KY, MD, NE, OR, TN, UT, WA
	Quetiapine	4	IL (1), TN (2), WA
	Risperidone	1	WA
Antiretroviral (10)	Emtricitabine	1	WA
Anxiolytic (1)	Buspirone	1	NE
Barbiturate (1)	Butalbital	3	IL (2), TN
Benzodiazepine (5)	7-amino Clonazepam**	3	KY, LA, TN
	Alpha-hydroxy Alprazolam**	2	NE, WA
	Alprazolam	9	CA, NE (2), TN (3), WA (3)
	Chlordiazepate	1	MD
	Diazepam	6	IL, MD, NE, TN (3)
	Lorazepam	10	CA (2), IL (2), KY (6), MA, OR
	Midazolam	6	IL, KY (2), MA, TN, UT
	Nordiazepam**	9	IL (2), MD, NE (2), TN (4)
	Oxazepam**	6	IL (2), MD, NE, TN (2)
	Temazepam**	4	IL, MD, TN (2)
Cardiovascular (7)	Amiodarone	3	KY, MD, NE
	Atorvastatin	3	TN, WA (2)
	Atropine	4	IN, TN (2), TX
	Clonidine	3	IL, KY, OR
	Labetalol	3	IL (2), TN
	Metoprolol	3	NE, TN (2)
	Propranolol	1	TN

\*\*Compounds are expected metabolites of parent drugs, as follow:

<b>Expected Metabolite</b>	<b>Parent Drug</b>
7-Amino Clonazepam	Clonazepam
Alpha-Hydroxy Alprazolam	Alprazolam
Nordiazepam	Diazepam
Oxazepam	Diazepam
Temazepam	Diazepam

**Table 3 (Continued). Prescription or OTC drugs in Biological Samples – Third Quarter 2023**

<b>Drug Class</b>	<b>Drug</b>	<b>Freq.</b>	<b>States Found*</b>
Cough Suppressant (2)	Dextromethorphan	2	MD, TN
	Dextrophan	2	MD, TN
Decongestant (1)	Phenylephrine	2	KY, TN
Muscle Relaxant (3)	Baclofen	1	MD
	Cyclobenzaprine	3	TN (2), WA
	Methocarbamol	3	FL, KY, OR
Opioid (3)	Buprenorphine	5	IL, IN, KY, MD, NE, TN
	EDDP**	6	IL, KY, LA, TN (3)
	EDMP**	1	TN
	Methadone	5	CA, IL, KY, LA, TN (3)
	Naloxone	30	CA (2), FL (2), IL (4), KY (6), MD (2), NE (3), NM, TN (10)
	Norbuprenorphine**	3	IL, IN, KY
Pain Reliever (2)	Acetaminophen	29	CA (4), FL, IL (4), KY (2), LA (2), MA, MD, NM, OR TN (8), WA (5)
	Naproxen	1	KY

\* CA – California; FL – Florida; IL – Illinois; IN – Indiana; KY – Kentucky; LA – Louisiana; MA – Massachusetts; MD – Maryland; NE – Nebraska; NM – New Mexico; OR – Oregon; TN – Tennessee; UT – Utah; WA– Washington

\*\*Compounds are expected metabolites of parent drugs, as follow:

<b>Expected Metabolite</b>	<b>Parent Drug</b>	<b>Expected Metabolite</b>	<b>Parent Drug</b>
EDDP	Methadone	Norbuprenorphine	Buprenorphine

§ - Parent drugs or metabolites are only counted once for the number of drugs detected in Tables 1-5. If only a metabolite is encountered in the absence of a parent drug, it will still be counted as a unique drug. Both parent drugs and metabolites are counted as detections.

## Dietary Supplement Stimulants

DEA TOX confirmed 8 detections of 3 DSS (Table 4) in biological samples in the fourth quarter of 2023. Three additional DSS detections from drug products are described in Table 6.

**Table 4. DSS Detected in Biological Samples – Fourth Quarter 2023**

Drug Class	Drug	Freq.	States Found*
Methyl Xanthine	Caffeine	6	CA (3), IL (2), MA
Phenethylamine	Hordenine	1	MD
Phenethylamine	<i>N</i> -Methyl Tyramine	1	CA

\*CA – California, IL – Illinois, MA – Massachusetts, MD – Maryland

## Precursors/Additives/Impurities

DEA TOX confirmed 73 detections of 5 P/A/§ (Table 5) in biological samples in the fourth quarter of 2023. Twelve additional P/A/I detections in drug products are described in Table 6.

**Table 5. P/A/I Detected in Biological Samples – Fourth Quarter 2023**

Drug Class	Drug	Freq.	States Found*	Confirmed Levels (ng/mL)**			
				S	P	WB	U
Adulterant (3)	4-Hydroxy-Xylazine***	1	IL				107
	Levamisole	2	KY, TN			0.4-8.1	
	Quinine	17	IL (4), KY, NE, TN (11)	19.8	7.3-18.6	0.6-373	50.5-794
	Xylazine	17	IL (2), KY (3), TN (12)			0.3-112	10600
Impurity (1)	<i>N,N</i> -dimethyl amphetamine	5	CA, NE (2), NM, TN	3780		0.3-62.3	88
Precursor (1)	4-ANPP	31	IL (2), KY (3), NE, TN (15), WA (10)	1.9	0.5-33.4	0.5-29.5	83.4

\*CA – California; IL – Illinois; KY – Kentucky; NE – Nebraska; NM – New Mexico; TN – Tennessee; WA – Washington

\*\*S – Serum; P – Plasma; WB – Whole Blood; U – Urine

\*\*\*4-Hydroxyxylazine is a metabolite of xylazine.

§ - Parent drugs or metabolites are only counted once for the number of drugs detected in Tables 1-5. If only a metabolite is encountered in the absence of a parent drug, it will still be counted as a unique drug. Both parent drugs and metabolites are counted as detections.

## Drug Products

DEA TOX confirmed 81 detections of 20 drugs (Table 6) in 20 drug product samples analyzed in the fourth quarter of 2023.

**Table 6. Drugs Detected in Drug Products – Fourth Quarter 2023**

Drug Class	Drug Subclass	Drug	Freq.	States Found*	Level
New Psychoactive Substances	Benzodiazepine (1)	Bromazolam	1	IL	15µg
	Opioid (7)	Acetyl Fentanyl	11	WA	0.08-590µg
		Despropionyl- <i>para</i> -Fluorofentanyl	4	WA(4)	1.3µg-1.8mg
		Etonitazene	1	WA	100µg
		Metonitazene	1	WA	32µg
		<i>N</i> -Desethyl Etonitazene	1	WA	35mg
		<i>para</i> -Fluoroacetylfentanyl	2	WA(2)	2.4-9.7µg
		<i>para</i> -Fluorofentanyl	3	WA(3)	3.8ug-22mg
Prescription or Over the Counter Medications	Pain Reliever (1)	Acetaminophen	4	WA(4)	20-890mg
	Antihistamine (1)	Diphenhydramine	1	IL	15.5mg
	Anticonvulsant (1)	Gabapentin	1	IL	54µg
	Abortifacient (1)	Misoprostol	1	CA	691ug
	Antidepressant (1)	Quetiapine	1	IL	3.2mg
Traditional Illicit Drugs	Cocaine (1)	Cocaine	7	IL, KY, WA(5)	0.97µg-170mg
		Benzoyllecgonine	1	WA	1.0mg
		Ecgonine Methyl Ester	1	WA	1.8mg
	Opioid (1)	Fentanyl	15	IL, KY(2), WA(12)	0.88-190mg
		Norfentanyl	8	IL, WA(7)	2.6-57µg
	Amphetamine (1)	Methamphetamine	2	KY, WA	92-120mg
Dietary Supplements, Stimulants	Stimulant (2)	Caffeine	2	IL, MA	0.25-2.8mg
		Theophylline	1	MA	8.6mg
Precursors, Additives, Impurities	Precursor (1)	4-ANPP	11	IL, KY, WA(9)	0.04-32mg
	Additive (1)	Quinine	1	IL	1.2mg

\*CA – California; IL – Illinois; KY – Kentucky; MA – Massachusetts; WA – Washington

**Drug Enforcement Administration – Toxicology Testing Program**

**Select Drug Product Exhibits:**


**Table 7. Drug Product Exhibit #1: Total Exhibit Weight: 183.5mg**

<b>Drug Class</b>	<b>Drug</b>	<b>State Found*</b>	<b>Confirmed Levels</b>	<b>Actual Amount within Drug Product</b>
TID	Methamphetamine	KY	680 mg/g	120mg
	Fentanyl		27 µg/g	5.0µg
	Cocaine		5.3 µg/g	0.97µg



**Table 8. Drug Product Exhibit #2: Total Exhibit Weight: 229.0mg**

<b>Drug Class</b>	<b>Drug</b>	<b>State Found*</b>	<b>Confirmed Levels</b>	<b>Actual Amount within Drug Product</b>
TID	Fentanyl	WA	830 mg/g	190mg
	Cocaine		27 mg/g	6.2mg
NPS	Acetyl Fentanyl		0.85 mg/g	0.19mg
P/A/I	4-ANPP		140 mg/g	32mg



**Drug Enforcement Administration – Toxicology Testing Program**

**Table 9. Drug Product Exhibit #3: Total Exhibit Weight: 108.5mg**

Drug Class	Drug	State Found*	Confirmed Levels	Actual Amount within Drug Product
PD	Acetaminophen	WA	820mg/g	89mg
TID	Fentanyl		8.6mg/g	0.93mg
NPS	<i>para</i> -Fluorofentanyl		35µg/g	3.8µg
	Despropionyl- <i>para</i> -Fluorofentanyl		12µg/g	1.3 µg
P/A/I	4-ANPP		9.8mg/g	1.1mg



**Table 10. Drug Product Exhibit #4: Total Exhibit Weight: 180.7mg**

Drug Class	Drug	State Found*	Confirmed Levels	Actual Amount within Drug Product
TID	Cocaine	WA	930mg/g	170mg
	Ecgonine Methyl Ester		9.7mg/g	1.8mg
	Benzoyllecgonine		5.7mg/g	1.0mg






**Drug Enforcement Administration – Toxicology Testing Program**


**Table 11. Drug Product Exhibit #5: Total Exhibit Weight: 232.9mg**

<b>Drug Class</b>	<b>Drug</b>	<b>State Found*</b>	<b>Confirmed Levels</b>	<b>Actual Amount within Drug Product</b>
NPS	<i>N</i> -Desethyl Etonitazene	WA	150mg/g	35mg
	Etonitazene		450µg/g	100µg
	Metonitazene		140µg/g	32µg



**Table 12. Drug Product Exhibit #6: Total Exhibit Weight: 154.2mg**


<b>Drug Class</b>	<b>Drug</b>	<b>State Found*</b>	<b>Confirmed Levels</b>	<b>Actual Amount within Drug Product</b>
PD	Misoprostol	CA	4.5mg/g	690µg



**Drug Enforcement Administration – Toxicology Testing Program**

**Table 13. Drug Product Exhibit #7: Total Exhibit Weight: 171.5mg**

<b>Drug Class</b>	<b>Drug</b>	<b>State Found*</b>	<b>Confirmed Levels</b>	<b>Actual Amount within Drug Product</b>
PD	Diphenhydramine	IL	90mg/g	16mg
	Quetiapine		19mg/g	3.2mg
	Gabapentin		0.32mg/g	54µg
TID	Fentanyl		21mg/g	3.6mg
	Cocaine		71µg/g	12µg
	Norfentanyl		21µg/g	3.6µg
P/A/I	Quinine		7.2mg/g	1.2mg
	4-ANPP		7.0mg/g	1.2mg
DSS	Caffeine		1.5mg/g	250µg
NPS	Bromazolam		89µg/g	15µg



\*CA – California; IL – Illinois; KY – Kentucky; WA – Washington

## Contact Information

We invite medical and law enforcement facilities to contact our program if you encounter an overdose of a suspected synthetic drug and desire to have any leftover biological samples (blood preferred) analyzed further for such synthetic substances.

- **Sample Qualifications:**

- Patients thought to have ingested a synthetic drug, where the traditional drug screen has produced little or no viable options to explain the symptoms exhibited by the patient (alcohol and THC are exempted).

- **How to Contact Us and Send Your Samples:**

- Once the above qualifications are satisfied:
  - Email [DEATOX@DEA.GOV](mailto:DEATOX@DEA.GOV) with a brief description of the case (including initial toxicology screen and history) and a request for testing.
  - DEA will respond to each inquiry, and if approved, will send the instructions for packing and shipping of sample(s) to UCSF.
    - The main reason for disapproval of a case would be the identification of substances including methamphetamine, heroin, fentanyl, cocaine, LSD, PCP etc. in a routine toxicology screening at your facility.
    - This program's goal is to connect symptom causation to abuse of newly emerging synthetic drugs (e.g. synthetic cannabinoids, synthetic cathinones, fentanyl-related substances, other hallucinogens etc.).
- Ensure that you de-identify and label the sample with a numerical value, sex, date of birth or age, and the date and time the sample was collected in accordance with the labeling instructions (sent with shipping instructions).
- Keep a master list of the patients and the numerical values you allocated to each sample at your institution.

- **Cost of Sample Analysis:**

- DEA will cover the full cost of testing the patient samples.
  - The sender will only be responsible for paying for packing and shipping samples to UCSF.

- **Turn-around Time:**

- Results are expected within three to four weeks of receipt of the sample at UCSF except in rare occurrences when a novel substance is identified.

## Public Domain Notice

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from the DEA. However, this publication may *not* be reproduced or distributed for a fee without the specific, written authorization of the U.S. Drug Enforcement Administration, U.S. Department of Justice. Citation of the source is appreciated.

### *Suggested citation:*

U.S. Drug Enforcement Administration, Diversion Control Division (2024). *DEA TOX: Quarterly Report – Fourth Quarter 2023*. Springfield, VA.

### **OBTAINING COPIES OF THIS PUBLICATION**

Electronic copies of this publication can be downloaded from the DEA TOX website at:

[https://www.deadiversion.usdoj.gov/dea\\_tox/dea-tox.html](https://www.deadiversion.usdoj.gov/dea_tox/dea-tox.html)

This report was produced in conjunction with the CTEB laboratory at UCSF.



**Clinical Toxicology  
and Environmental Biomonitoring Laboratory**

**DEA PRB-2024-05**